Pfizer Price to Book Ratio 2012-2025 | PFE
Historical price to book ratio values for Pfizer (PFE) over the last 10 years. The current price to book ratio for Pfizer as of April 09, 2026 is 1.68.
| Pfizer Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-04-10 | 26.92 | 1.64 | |
| 2025-09-30 | 24.63 | $16.37 | 1.50 |
| 2025-06-30 | 23.03 | $15.66 | 1.47 |
| 2025-03-31 | 23.63 | $15.94 | 1.48 |
| 2024-12-31 | 24.33 | $15.62 | 1.56 |
| 2024-09-30 | 26.14 | $16.34 | 1.60 |
| 2024-06-30 | 24.92 | $15.52 | 1.61 |
| 2024-03-31 | 24.35 | $16.33 | 1.49 |
| 2023-12-31 | 24.88 | $15.81 | 1.57 |
| 2023-09-30 | 28.29 | $17.22 | 1.64 |
| 2023-06-30 | 30.94 | $17.59 | 1.76 |
| 2023-03-31 | 34.04 | $17.93 | 1.90 |
| 2022-12-31 | 42.37 | $17.08 | 2.48 |
| 2022-09-30 | 35.87 | $16.55 | 2.17 |
| 2022-06-30 | 42.65 | $15.64 | 2.73 |
| 2022-03-31 | 41.77 | $14.79 | 2.82 |
| 2021-12-31 | 47.29 | $13.78 | 3.43 |
| 2021-09-30 | 34.14 | $13.54 | 2.52 |
| 2021-06-30 | 30.81 | $12.56 | 2.45 |
| 2021-03-31 | 28.22 | $12.31 | 2.29 |
| 2020-12-31 | 28.37 | $11.40 | 2.49 |
| 2020-09-30 | 26.56 | $11.79 | 2.25 |
| 2020-06-30 | 23.44 | $11.62 | 2.02 |
| 2020-03-31 | 23.16 | $11.77 | 1.97 |
| 2019-12-31 | 27.52 | $11.46 | 2.40 |
| 2019-09-30 | 25.00 | $11.82 | 2.11 |
| 2019-06-30 | 29.86 | $10.77 | 2.77 |
| 2019-03-31 | 29.02 | $10.65 | 2.73 |
| 2018-12-31 | 29.57 | $11.15 | 2.65 |
| 2018-09-30 | 29.62 | $12.40 | 2.39 |
| 2018-06-30 | 24.18 | $11.96 | 2.02 |
| 2018-03-31 | 23.42 | $12.06 | 1.94 |
| 2017-12-31 | 23.69 | $11.98 | 1.98 |
| 2017-09-30 | 23.14 | $10.25 | 2.26 |
| 2017-06-30 | 21.56 | $9.87 | 2.18 |
| 2017-03-31 | 21.74 | $9.84 | 2.21 |
| 2016-12-31 | 20.44 | $9.86 | 2.07 |
| 2016-09-30 | 21.10 | $10.48 | 2.01 |
| 2016-06-30 | 21.75 | $10.40 | 2.09 |
| 2016-03-31 | 18.15 | $10.44 | 1.74 |
| 2015-12-31 | 19.57 | $10.53 | 1.86 |
| 2015-09-30 | 18.89 | $10.87 | 1.74 |
| 2015-06-30 | 20.01 | $10.89 | 1.84 |
| 2015-03-31 | 20.59 | $10.98 | 1.88 |
| 2014-12-31 | 18.28 | $11.38 | 1.61 |
| 2014-09-30 | 17.20 | $12.43 | 1.38 |
| 2014-06-30 | 17.11 | $12.14 | 1.41 |
| 2014-03-31 | 18.36 | $12.24 | 1.50 |
| 2013-12-31 | 17.36 | $11.97 | 1.45 |
| 2013-09-30 | 16.16 | $12.09 | 1.34 |
| 2013-06-30 | 15.63 | $11.93 | 1.31 |
| 2013-03-31 | 15.97 | $11.68 | 1.37 |
| 2012-12-31 | 13.75 | $11.23 | 1.23 |
| 2012-09-30 | 13.51 | $11.15 | 1.21 |
| 2012-06-30 | 12.39 | $10.71 | 1.16 |
| 2012-03-31 | 12.08 | $11.17 | 1.08 |
| 2011-12-31 | 11.42 | $10.91 | 1.05 |
| 2011-09-30 | 9.24 | $11.78 | 0.78 |
| 2011-06-30 | 10.65 | $11.40 | 0.93 |
| 2011-03-31 | 10.40 | $11.46 | 0.91 |
| 2010-12-31 | 8.87 | $11.02 | 0.81 |
| 2010-09-30 | 8.61 | $10.99 | 0.78 |
| 2010-06-30 | 7.07 | $10.81 | 0.65 |
| 2010-03-31 | 8.41 | $11.17 | 0.75 |
| 2009-12-31 | 8.84 | $11.21 | 0.79 |
| 2009-09-30 | 7.97 | $8.21 | 0.97 |
| 2009-06-30 | 7.15 | $9.37 | 0.76 |
| 2009-03-31 | 6.42 | $8.96 | 0.72 |
| 2008-12-31 | 8.17 | $8.56 | 0.95 |
| 2008-09-30 | 8.36 | $9.99 | 0.84 |
| 2008-06-30 | 7.79 | $9.88 | 0.79 |
| 2008-03-31 | 9.19 | $9.97 | 0.92 |
| 2007-12-31 | 9.84 | $9.62 | 1.02 |
| 2007-09-30 | 10.45 | $9.75 | 1.07 |
| 2007-06-30 | 10.80 | $9.83 | 1.10 |
| 2007-03-31 | 10.56 | $10.33 | 1.02 |
| 2006-12-31 | 10.71 | $10.02 | 1.07 |
| 2006-09-30 | 11.63 | $9.67 | 1.20 |
| 2006-06-30 | 9.53 | $9.39 | 1.01 |
| 2006-03-31 | 10.03 | $9.50 | 1.06 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $156.812B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |